Travere Therapeutics, Inc. (TVTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250M 500M 750M Q2 '11: 0 Q3 '11: 0 Q4 '11: 0 Q4 '17: 154.9M Q1 '18: 159.7M Q2 '18: 162.3M Q3 '18: 162.7M Q4 '18: 164.2M Q1 '19: 165.4M Q2 '19: 168.8M Q3 '19: 172.4M Q4 '19: 175.3M Q1 '20: 183.5M Q2 '20: 187.3M Q3 '20: 194M Q4 '20: 198.3M Q1 '21: 198M Q2 '21: 204.1M Q3 '21: 221.2M Q4 '22: 160.1M Q1 '23: 142.5M Q2 '23: 120.5M Q3 '23: 129.5M Q4 '23: 145.2M Q1 '24: 155.7M Q2 '24: 177.6M Q3 '24: 203.4M Q4 '24: 233.2M Q1 '25: 273.5M Q2 '25: 333.9M Q3 '25: 435.8M Q4 '25: 490.7M Q1 '26: 536.2M Q2 '26: 591.3M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 200M 400M 600M Q2 '18: 157.4M Q3 '18: 157.6M Q4 '18: 158.7M Q1 '19: 160.5M Q2 '19: 164M Q3 '19: 167.3M Q4 '19: 170.1M Q1 '20: 177.9M Q2 '20: 181.2M Q3 '20: 188.2M Q4 '20: 192.2M Q1 '21: 191.6M Q2 '21: 197.6M Q3 '21: 214.3M Q4 '22: 153.9M Q1 '23: 134.3M Q2 '23: 112.9M Q3 '23: 121.8M Q4 '23: 133.8M Q1 '24: 146.9M Q2 '24: 168.2M Q3 '24: 193.7M Q4 '24: 225.4M Q1 '25: 262.6M Q2 '25: 323.5M Q3 '25: 425.5M Q4 '25: 480.4M Q1 '26: 528.6M Q2 '26: 583.1M Q2 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '12: -30.3M Q1 '13: -28.6M Q2 '13: -28.9M Q3 '13: -26.5M Q4 '13: -24.9M Q3 '14: -72.8M Q4 '14: -79.8M Q3 '15: -54.2M Q4 '15: -50.7M Q1 '16: -50.9M Q2 '16: -55.3M Q3 '16: -55.2M Q4 '16: -58.2M Q1 '17: -64.4M Q2 '17: -66.6M Q3 '17: -56.8M Q4 '17: -53.8M Q1 '18: -57.3M Q2 '18: -65.3M Q3 '18: -90.2M Q4 '18: -80M Q1 '19: -100.4M Q2 '19: -115.3M Q3 '19: -114.2M Q4 '19: -137.4M Q1 '20: -114.2M Q2 '20: -100.8M Q3 '20: -85.8M Q4 '20: -176.2M Q1 '21: -208.6M Q2 '21: -220.8M Q3 '21: -233.1M Q4 '21: -199.4M Q1 '22: -218M Q2 '22: -248.1M Q3 '22: -299M Q4 '22: -300.9M Q1 '23: -332.1M Q2 '23: -370.6M Q3 '23: -380.6M Q4 '23: -388.1M Q1 '24: -430M Q2 '24: -393.8M Q3 '24: -357.3M Q4 '24: -323.8M Q1 '25: -227.3M Q2 '25: -172.2M Q3 '25: -91.1M Q4 '25: -62.8M Q1 '26: -57.1M Q2 '26: -40.5M Q1 '13 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q2 '11: -19.9K Q3 '11: -16.8K Q4 '11: -14.6K Q3 '13: -35.5M Q4 '13: -34.8M Q3 '14: -94.5M Q4 '14: -110.9M Q3 '15: 90.7M Q4 '15: 117.2M Q1 '16: 88.8M Q2 '16: 100.9M Q3 '16: -41.8M Q4 '16: -47.9M Q1 '17: -70.2M Q2 '17: -70M Q3 '17: -50.7M Q4 '17: -59.7M Q1 '18: -67M Q2 '18: -76.1M Q3 '18: -112.8M Q4 '18: -102.7M Q1 '19: -125.3M Q2 '19: -141.6M Q3 '19: -123.6M Q4 '19: -146.4M Q1 '20: -104.6M Q2 '20: -92M Q3 '20: -78.1M Q4 '20: -169.4M Q1 '21: -224.1M Q2 '21: -237.1M Q3 '21: -250.1M Q4 '21: -180.1M Q1 '22: -202.2M Q2 '22: -230.2M Q3 '22: -264.2M Q4 '22: -278.5M Q1 '23: -288.8M Q2 '23: -307.4M Q3 '23: -87M Q4 '23: -111.4M Q1 '24: -161.1M Q2 '24: -145.9M Q3 '24: -351.5M Q4 '24: -321.5M Q1 '25: -226.7M Q2 '25: -169.1M Q3 '25: -88.5M Q4 '25: -25.5M Q1 '26: -21.4M Q2 '26: -43.5M Q3 '11 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

0 4M 8M 12M Q2 '18: 4.9M Q3 '18: 5.1M Q4 '18: 5.5M Q1 '19: 4.9M Q2 '19: 4.7M Q3 '19: 5.1M Q4 '19: 5.2M Q1 '20: 5.6M Q2 '20: 6.1M Q3 '20: 5.8M Q4 '20: 6.1M Q1 '21: 6.4M Q2 '21: 6.6M Q3 '21: 7M Q4 '22: 6.2M Q1 '23: 8.2M Q2 '23: 7.6M Q3 '23: 7.8M Q4 '23: 11.4M Q1 '24: 8.8M Q2 '24: 9.4M Q3 '24: 9.8M Q4 '24: 7.7M Q1 '25: 10.9M Q2 '25: 10.4M Q3 '25: 10.3M Q4 '25: 10.3M Q1 '26: 7.6M Q2 '26: 8.3M Q2 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '11: -720 Q4 '11: -647 Q2 '13: -7.9M Q3 '13: -9.8M Q4 '13: -17.6M Q1 '14: -22.8M Q2 '14: -32.1M Q3 '14: -45.2M Q4 '14: -45.9M Q1 '15: -42.6M Q2 '15: -23.2M Q3 '15: -6.9M Q4 '15: -1.4M Q1 '16: 1.6M Q2 '16: -2.4M Q3 '16: 1.5M Q4 '16: -3.4M Q1 '17: -3.3M Q2 '17: -1.2M Q3 '17: 323K Q4 '17: 7.4M Q1 '18: -3.9M Q2 '18: -12.7M Q3 '18: -22.8M Q4 '18: -25M Q1 '19: -30.7M Q2 '19: -47.1M Q3 '19: -57.3M Q4 '19: -58.2M Q1 '20: -66.9M Q2 '20: -54.2M Q3 '20: -33.4M Q4 '20: -42.7M Q1 '21: -40.1M Q2 '21: -27.1M Q3 '21: -1.8M Q4 '21: -14.8M Q1 '22: -43.6M Q2 '22: -86.9M Q3 '22: -158.5M Q4 '22: -186.3M Q1 '23: -212.1M Q2 '23: -244.6M Q3 '23: -264.2M Q4 '23: -280M Q1 '24: -317.9M Q2 '24: -288.9M Q3 '24: -272.2M Q4 '24: -237.5M Q1 '25: -160.7M Q2 '25: -115.4M Q3 '25: -58.6M Q2 '13 Q1 '15 Q4 '16 Q3 '18 Q2 '20 Q1 '22 Q4 '23 Q3 '25

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '13: -7.9M Q3 '13: -9.9M Q4 '13: -17.7M Q1 '14: -23.1M Q2 '14: -32.6M Q3 '14: -45.8M Q4 '14: -46.5M Q1 '15: -43.2M Q2 '15: -23.4M Q3 '15: -7M Q4 '16: -4.9M Q1 '17: -5.5M Q2 '17: -3.7M Q3 '17: -2.5M Q4 '18: -25.7M Q1 '19: -31.4M Q2 '19: -47.2M Q3 '19: -57.6M Q4 '20: -49.5M Q1 '21: -51.1M Q2 '21: -38M Q3 '21: -10.6M Q4 '21: -19.9M Q1 '22: -44.4M Q2 '22: -87.6M Q3 '22: -158.8M Q4 '22: -186.5M Q1 '23: -212.8M Q2 '23: -245.3M Q3 '23: -264.9M Q4 '23: -280.7M Q1 '24: -317.9M Q2 '24: -289M Q3 '24: -272.3M Q1 '14 Q2 '15 Q3 '17 Q4 '20 Q1 '22 Q2 '23 Q3 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '13: 12.3M Q3 '13: 15.4M Q1 '14: 23.3M Q2 '14: 27.3M Q3 '14: 28.2M Q1 '15: 30.4M Q2 '15: 35M Q3 '15: 42.8M Q1 '16: 37.9M Q2 '16: 36.7M Q3 '16: 37M Q1 '17: 39.2M Q2 '17: 39M Q3 '17: 38.7M Q1 '18: 39.7M Q1 '19: 41.4M Q1 '20: 43.6M Q2 '20: 44.8M Q3 '20: 50.9M Q1 '21: 56.3M Q2 '21: 60.6M Q3 '21: 60.8M Q1 '22: 63.1M Q2 '22: 63.6M Q3 '22: 64M Q1 '23: 68.2M Q2 '23: 76M Q3 '23: 76.3M Q1 '24: 77.1M Q2 '24: 77.5M Q3 '24: 77.8M Q1 '25: 88.4M Q2 '25: 88.9M Q3 '25: 102.6M Q1 '26: 91.9M Q2 '26: 93.5M Q2 '13 Q1 '15 Q3 '16 Q1 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '13: -4.32 Q4 '13: -2.40 Q3 '14: -5.56 Q4 '14: -5.96 Q3 '15: 1.27 Q4 '15: 2.23 Q1 '17: -2.08 Q2 '17: -2.05 Q3 '17: -1.51 Q4 '17: -1.67 Q1 '18: -1.81 Q2 '18: -2.03 Q3 '18: -2.91 Q4 '18: -2.54 Q1 '19: -3.07 Q2 '19: -3.43 Q3 '19: -2.94 Q4 '19: -3.46 Q1 '20: -2.45 Q2 '20: -2.11 Q3 '20: -1.70 Q4 '20: -3.53 Q1 '21: -4.51 Q2 '21: -4.57 Q3 '21: -4.72 Q4 '21: -3.03 Q1 '22: -3.27 Q2 '22: -3.68 Q3 '22: -4.18 Q4 '22: -4.37 Q1 '23: -4.44 Q2 '23: -4.52 Q3 '23: -1.46 Q4 '23: -1.61 Q1 '24: -2.10 Q2 '24: -1.88 Q3 '24: -4.55 Q4 '24: -4.08 Q1 '25: -2.79 Q2 '25: -2.02 Q3 '25: -1.04 Q4 '25: -0.29 Q1 '26: -0.22 Q2 '26: -0.45 Q4 '13 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.